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Abstract Metabolic gene polymorphisms have previously
been suggested as risk factors for renal cell carcinoma
(RCC). These polymorphisms are involved in activation or
detoxiWcation of carcinogens in cigarette smoke which is
another RCC risk factor. We evaluated gene–environment
interactions between CYP1A1, GST1 and smoking in a
large population-based RCC case group. The Netherlands
Cohort Study on diet and cancer (NLCS) comprises 120,852
persons who completed a questionnaire on smoking and
other risk factors at baseline. After 11.3 years of follow-up,
337 incident RCC cases were identiWed. DNA was collected
for 245 cases. In a case-only analysis, interaction-odds ratios
(OR) and 95% conWdence intervals (95% CI) were calcu-
lated using logistic regression. We observed a moderate, not
statistically signiWcant, interaction between current smoking
and CYP1A1*2C (OR 1.42; 95% CI 0.70–2.89) and GST1
null (OR 1.35; 95% CI 0.65–2.79). For current smokers with
both a variant (heterozygous or homozygous) in CYP1A1
and GST1 null, risk was also increased (OR 1.63; 95% CI
0.63–4.24). No interaction was observed between ever
smokers, smoking duration (increments of 10 smoking
years) or amount (increments of 5 cigarettes/day) and
CYP1A or GST1. Our results show a modest trend towards
a statistically signiWcant gene–environment interaction
between CYP1A1, GST1 and smoking in RCC. This could
indicate that RCC risk among smokers might be more
increased with the CYP1A1*2C genotype, GST1 null, or
both a CYP1A1 variant and GST1 null.
Keywords CYP1A1 genotype · Gene–environment 
interaction · GST1 genotype · Smoking · Renal cell cancer
Introduction
Renal cell carcinoma (RCC) is the ninth most common
tumour in the European Union [1, 2] with a worldwide inci-
dence of 4.7 per 100,000 person years for men and 2.2 per
100,000 person years for women (http://www-dep.iarc.fr).
Incidence rates rise steadily in industrialized countries [3].
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104 World J Urol (2008) 26:103–110Previous studies have identiWed smoking as a risk factor for
the development of RCC [2, 4–8] with a relative risk of 1.45
for current smokers with a strong dose-dependent increase in
risk [9]. In addition to environmental risk factors, several
researchers have focused on molecular markers and have
described several genetic polymorphisms that are potential
risk factors for RCC e.g. [3, 10–15]. Among others, polymor-
phisms in genes that code for xenobiotic-metabolizing
enzymes have been proposed as possible risk factors for RCC
since these enzymes are involved in the activation of pro-car-
cinogenic compounds or detoxiWcation of carcinogens [3].
CYP1A1 is a phase I enzyme that is involved in the met-
abolic activation of polycyclic aromatic hydrocarbons
(PAHs), such as bezo[a]pyrenediolepoxide, which are
found in cigarette smoke. Previous studies have described
several polymorphisms in the CYP1A1 gene, of which two
(CYP1A1*2A and CYP1A1*2C) have been described exten-
sively [16]. CYP1A1*2A is a T to C transition in the 3 non-
coding region of the CYP1A1 gene. CYP1A1*2A causes an
higher conversion of PAHs to electrophilic molecules
which can react with DNA. CYP1A1*2C is an A to G tran-
sition in exon 7, this transition is associated with a twofold
increase in microsomal activity of the CYP1A1 enzyme
[16] as compared to the wildtype although not consistently
[17]. CYP1A1*2A and CYP1A1*2C have been found to be
associated with an increased risk of RCC [3].
Most carcinogens are detoxiWed by phase II enzymes
such as GST1. GST1 metabolizes, among others, reac-
tive epoxides of PAHs. The gene that codes for GST1 has
been found to be homozygously deleted in 40–50% of the
Caucasian population resulting in an absence of enzyme
activity. This GST1 null genotype is associated with sus-
ceptibility to several forms of cancer [3].
Since cigarette smoking and metabolic gene polymor-
phisms may be associated with RCC development, RCC risk
may be even more increased after cigarette smoke exposure
in the presence of certain genotypes. In this study, we
evaluated the gene–environment interaction between
CYP1A1*2A, CYP1A1*2C and GST1 null and smoking in
patients with RCC. Since there are no indications that smok-
ing behaviour is associated with CYP1A1*2A, CYP1A1*2C
or GST1 null, a case-only design is an eYcient method to
estimate a possible gene–environment interaction. However,
the main eVects of CYP1A1*2A, CYP1A1*2C or GST1 null
or smoking cannot be assessed in a case-only design.
Materials and methods
Study population
The Netherlands Cohort Study on diet and cancer (NLCS)
is a prospective cohort study, initiated in 1986 with the
enrolment of 120,852 men and women. The study design
has been reported in detail elsewhere [18]. BrieXy, at base-
line a total of 58,279 men and 62,573 women, aged 55–
69 years old, were included. All cohort members completed
a self-administered questionnaire on dietary habits, life-
style, smoking, personal and family history of cancer and
demographic data at baseline. Tobacco smoking was
assessed as smoking status (never, ex and current), age at
Wrst and last exposure, smoking frequency, smoking dura-
tion and cigar and pipe smoking. Information on smoking
status was available for all cases. Incident cancer cases are
identiWed by computerized record linkage with the Nether-
lands Cancer Registry (NCR) and PALGA, a national data-
base of pathology reports. The method of record linkage to
obtain information on cancer incidence has been described
in detail previously [19]. The completeness of follow-up
was estimated to be over 96%. From 1986 to 1997, 355 kid-
ney cancer cases (ICD-O-3:C64.9) were identiWed within
the cohort. Urothelial cell carcinomas were excluded and
only histologically conWrmed renal cell cancers were
included (ICD-O: M8010–8119, 8140–8570), leaving 337
cases.
Tissue samples
Tumour material and healthy tissue samples of kidney can-
cer patients were collected after approval by the Ethical
Review Board of Maastricht University, the NCR and
PALGA. For 273 of the 337 eligible cases, a PALGA
record with information on the location of tissue blocks was
available. We were able to collect DNA material for 251
cases. All HE-stained slides were reviewed by an experi-
enced genitourinary pathologist. Tissue collection has been
described in detail elsewhere [20]. RCCs were classiWed
according to the World Health Organization classiWcation
of tumours from 2002 [21].
For 248 out of 251 cases, CYP1A1 and GST1 geno-
types were determined. Material of three cases was addi-
tionally discarded after revision because of the fact that
only material from a metastasis or a biopsy was available.
We used normal tissue for 191 persons and tumour mate-
rial for 57 patients since normal tissue was not available
for all cases. To check if CYP1A1 and GST1 genotypes
diVer in normal tissue compared to tumour tissue, we per-
formed a pilot study and selected 40 samples for each
genotype (20 from normal tissue and 20 from tumour tis-
sue) to compare genotypes in normal tissue and tumour
tissue. We observed no diVerences in the studied geno-
types between normal tissue and tumour tissue and there-
fore used both tissue types for the interaction analyses.
Three cases have not been genotyped due to administra-
tive problems. As a result, 245 cases were available for
further analysis.123
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DNA was extracted as described previously [20]. In brief,
paraYn was removed with xylene and DNA was extracted
by salt-precipitation. CYP1A1 and GST1 genotypes were
analyzed by restriction fragment length polymorphism
polymerase chain reaction (RFLP-PCR) and single speciWc
primer polymerase chain reaction (SSP-PCR).
CYP1A1
CYP1A1*2A genotype was determined using forward
primer GGCCCCAACTACTCAGAGGC and reverse
primer CAGTGAAGAGGTGTAGCCGCT. PCR products
were digested with MspI and separated by gel electrophore-
sis on 4% agarose gels and stained with ethidium bromide
resulting in an undigested 180 bp fragment for the wildtype
genotype (TT), three fragments (44, 136 and 180 bp) for
the heterozygous genotype (TC) or two fragments (44 and
136 bp) for the homozygous variant (CC).
CYP1A1*2C genotype was determined as previously
described [22]. A forward primer GGTCAACCCATCTGA
GTTCC was used together with the reverse primer CCAGG
AAGAGAAAGACCTCCCAGCGGGCCA. PCR products
were digested with NcoI restriction enzymes and, separated
by gel electrophoresis on 4% agarose gels and stained with
ethidium bromide, resulting in an undigested 151 bp frag-
ment for the wildtype AA genotype, three fragments (31,
120 and 151 bp) for the heterozygous genotype (AG) and
two fragments (31 and 120 bp) for the GG genotype.
GST1
GST1 genotype was determined as described before by
Fryer and colleagues [23] by SSP-PCR. Forward primer
GCTTCACGTGTTATGGAGGTTC was used together
with reverse primer: TTGGGAAGGCGTCCAAGCAC.
Two additional primers for VHL were added as internal
controls (forward: CACTGAGGATTTGGT TTT TGC and
reverse TCCAGGTCTTTCTGCACATTT). PCR products
were separated by gel electrophoresis on 4% agarose gel
and stained with ethidium bromide. GST1 null is seen as a
complete deletion of the gene and thus as a failure to
amplify DNA.
CYP1A1*2A genotype could not be determined for four
cases, CYP1A1*2C could be determined for all cases and
GST1 could not be determined for six cases.
Statistical analyses
Data analyses were performed on 245 cases with available
smoking status. Interactions between smoking, CYP1A1*2A,
CYP1A1*2C or GST1 genotype and RCC risk were
assessed by use of a case-only design. The association
between genotype and smoking status among RCC patients
was assessed with logistic regression analysis in which
smoking was the dependent variable and genotype the inde-
pendent variable. In this analysis, the odds ratio (OR) and
corresponding 95% conWdence intervals (CI) for the associ-
ation between smoking status and genotype estimate the
departure of the gene and environment joint eVects from
multiplicative interaction. In the absence of interaction, this
OR is expected to be 1. Using this approach, statistical
power is increased. Results were considered to be statisti-
cally signiWcant if P · 0.05.
Smoking status contrasts in the analyses were deWned as
never versus ever (ex- and current-smokers) and non-cur-
rent (never and ex-smokers) versus current smokers. To
assess dose–response trends, analyses were performed for
years of smoking (per 10 years of smoking) and the number
of cigarettes smoked a day (per 5 cigarettes a day).
CYP1A1*2A, CYP1A1*2C and GST1 genotypes were
combined to assess the joint eVects on RCC risk. Patients
with CYP1A1*2A wildtype (TT), CYP1A1*2C (AA) wild-
type and presence of GST1 (heterozygous or homozy-
gous) were considered as the reference group. Due to the
low numbers of patients homozygous for CYP1A1*2A or
CYP1A1*2C, these groups were combined. Patients with
heterozygosity or homozygosity of CYP1A1*2A or
CYP1A1*2C were considered as the variant CYP1A1 group.
In case-only studies of interaction, analyses should be
controlled for covariates that possibly inXuence the inde-
pendence between the genetic factor and the environmen-
tal factor by including these factors in the analyses [24].
Age at baseline (years), sex, family history of RCC (yes/
no), body mass index (kg/m2), alcohol consumption (g/
day), hypertension (yes/no), use of antihypertensive med-
ication (yes/no), diabetes (yes/no), physical activity in lei-
sure time (<30, 30–60, 60–90, >90 min/day), intake of
fruit and vegetables (g/day) and pipe smoking (never, ex,
current) were considered as potential confounders. The
variables that were found to inXuence the risk estimates
by more than 10% were included in the model. Confound-
ers that were entered in the model were age at baseline,
gender, BMI, alcohol consumption, physical activity,
hypertension and pipe smoking. Since information of
BMI was missing in several cases, we substituted the
missing value by the median BMI value of the complete
case group and added an indicator variable for missing
values of BMI.
Results
Table 1 presents baseline characteristics for the 245 cases
that were included in the analyses. The mean age of our123
106 World J Urol (2008) 26:103–110population was 61.9 years and the majority, 64.1%, of the
patients were men. Most patients, 98.8%, did not have a
family history of RCC and had not reported diabetes
(96.3%) or hypertension (71.8%) at baseline. Since the
homozygote variants for CYP1A1*2A and CYP1A1*2C
were rare (0.8% for 2A and 3.3% for 2C), patients with
homozygote and heterozygote variants for CYP1A1 were
combined in the analyses to increase power.
Table 2 presents the logistic regression results on the
association between CYP1A1 and GST1 genotype and
smoking among RCC patients from the NLCS. We observed
moderate departure, although not statistically signiWcant,
from multiplicative interaction between the CYP2A1*2C
heterozygous or homozygous genotype and current versus
non-current smoking; OR 1.42 (95% CI 0.70–2.89) and
between GST1 null and current versus non-current smok-
ing; OR 1.35 (95% CI 0.65–2.79). Also, for the group with
both a variant in CYP1A1 and GST1 null genotype, we
observed a moderate interaction, although not statistically
signiWcant, between genotype and current versus non-cur-
rent smoking; OR 1.63 (95% CI 0.63–4.24). No interaction
was observed between any of the genotypes and ever versus
never smoking or between the genotypes and an increment
of 10 smoking years or 5 cigarettes/day.
Discussion
Polymorphisms in metabolic genes may alter the risk of
cancer by activation of pro-carcinogens or detoxiWcation of
carcinogens [3]. CYP1A1 polymorphisms and GST1 null
genotype have been associated with an increased risk of
several types of cancer, among which lung cancer, pancre-
atic cancer and colorectal cancer, although not consistently
[25, 26]. Up till now, few studies have considered the inXu-
ence of CYP1A1 and GST1 genotype on RCC risk.
CYP1A1 genotype has previously been found to be associ-
ated with an increased risk of RCC [3]. GST1 genotype
has not been associated with an alteration in RCC risk.
However, it was suggested that GST1 genotype modiWed
RCC risk in combination with other genotypes [3]. Since
CYP1A1 and GST1 genotype are involved in the metabo-
lism of carcinogens in cigarette smoke, a known risk factor
for RCC [9], genotype and smoking may have a synergistic
eVect on RCC risk.
In the present study, we evaluated a possible gene–envi-
ronment interaction between CYP1A1 and GST1 genotype
and smoking in patients with RCC. We observed moderate
departure from multiplicative interaction between
CYP1A1*2C heterozygosity or homozygosity and current
versus non-current smoking and between GST1 null and
current versus non-current smoking. Moreover, our obser-
vations suggest an interaction between patients with both a
variant in CYP1A1 and GST1 null genotype and current
versus non-current smoking. Our study implies that poly-
morphisms in metabolic genes might increase susceptibility
to RCC, possibly by interfering with the detoxiWcation of
carcinogens present in cigarette smoke. However, none of
the observed associations reached statistical signiWcance
although we observed a modest trend towards statistical
signiWcance.
Table 1 Description of baseline characteristics for renal cell cancer
cases, Netherlands Cohort Study on diet and cancer, 1986–1997
a heterozygous variant: CYP1A1*2A (TC), CYP1A1*2C (AG) &
homozygous variant: CYP1A1*2A (CC), CYP1A1*2C (GG)
Total population (N, %) 245 (100)
Patient characteristics
Age (mean, SD) 61.9 (3.89)
Gender (male, N,%) 157 (64.1)
Family history (No., N,%) 242 (98.8)
BMI (kg/m2, mean, SD) 25.41 (2.89)
Alcohol (mean, SD, grams) 11.01 (14.56)
Diabetes (No., N, %) 236 (96.3)
Hypertension (No., N, %) 176 (71.8)
Antihypertensive medication (No., N, %) 225 (91.8)
Physical activity (<30 min/day) (N, %) 54 (22.4)
Physical activity (30–60 min/day) (N, %) 73 (30.3)
Physical activity (60–90 min/day) (N,%) 49 (20.3)
Physical activity (>90 min/day) (N, %) 65 (27.0)
Smoking information
Never smoker (N, %) 64 (26.1)
Current smoker (N, %) 86 (35.1)
Ex-smoker (N, %) 95 (38.8)
Zero years of smoking (N, %) 64 (26.7)
One to 40 years of smoking (N, %) 102 (42.5)
>40 years of smoking (N, %) 74 (30.8)
Genotype information
CYP1A1*2A
Wildtype (TT) (N, %) 212 (88.0)
Heterozygote (TC) (N, %) 27 (11.2)
Homozygote (CC) (N, %) 2 (0.8)
CYP1A1*2C
Wildtype (AA) (N, %) 172 (70.2)
Heterozygote (AG) (N, %) 65 (26.5)
Homozygote (GG) (N, %) 8 (3.3)
GST1
Present (N, %) 87 (36.4)
Null (N, %) 152 (63.6)
CYP1A1 wildtype & GST1 wildtype (N, %) 57 (23.8)
CYP1A1 varianta & GST1 wildtype (N, %) 30 (12.6)
CYP1A1 wildtype & GST1 null (N, %) 100 (41.8)
CYP1A1 varianta & GST1 null (N, %) 52 (21.8)123
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108 World J Urol (2008) 26:103–110We did not observe a departure from multiplicative
interaction between genotype and ever versus never smok-
ers or between genotype and an increment of 10 years of
smoking or 5 cigarettes/day. Unexpectedly, for ever versus
never smoking, ORs dropped below 1. This could indicate
that ever smoking is not the optimal variable to use in anal-
yses on the association between CYP1A1 and GST1 geno-
type and smoking in patients with RCC.
As a moderate, but not statistically signiWcant, departure
from multiplicative interaction was only observed in current
versus non-current smokers, this could imply that in patients
with a high-risk genotype, smoking is involved in tumour
promotion rather than tumour initiation. Tumour promotion
requires multiple exposures to the carcinogens in cigarette
smoke before the development of a tumour. Hypothetically,
it is possible that RCC risk in smokers is only increased
among patients with both a variant in CYP1A1 and GST1
null genotype after several recent exposures to the carcino-
gens from tobacco smoke. Previously, an association
between RCC and the number of cigarettes smoked per day
was suggested in our population [2], however, we did not
observe an interaction between CYP1A1, GST1 genotype
and an increment of 10 years of smoking or 5 cigarettes/day.
It would have been interesting to evaluate the inXuence of
CYP1A1*2A, CYP1A1*2C and GST1 genotype in more
subgroups of smoking, such as ex-smokers. However, this
was not possible in our study due to the population size.
For several types of cancer, such as lung cancer,
CYP1A1*2A, CYP1A1*2C and GST1 genotype have pre-
viously been associated with an increase in the smoking-
related cancer risk. Based on a review of the literature,
Vineis and colleagues reported an overall RR of lung can-
cer in Caucasian patients with the CYP1A1*2A variant of
1.04 (95% CI 0.85–1.27), an RR of 1.30 (95% CI 0.89–
1.90) for the CYP1A1*2C variant and an RR of 1.21 (95%
CI 1.06–1.39) for patients with GST1 null [27].
Many genes are thought to be involved in the develop-
ment of RCC or in the metabolism of carcinogens. In our
study we evaluated only two genes, CYP1A1 and GST1.
However, the choice to assess the inXuence of these two
genes was hypothesis-driven, based on previous informa-
tion that suggests an association with RCC. In addition,
these genes are known to be involved in the metabolism of
carcinogenic compounds such as cigarette smoke, either
through activation of the carcinogen (CYP1A1) or through
detoxiWcation (GST1). Previous studies have shown that
polymorphisms in CYP1A1 are functional, leading to
increased CYP1A1 inducibility and increased enzymatic
activity [16]. However, Zhang et al. [17] suggested that
associations between lung cancer and CYP1A1*2C are pos-
sibly not the result of an increased carcinogen bioactivation
as they found only minor diVerences in kinetic behaviour
between the variant CYP1A1 proteins.
GST1 null genotype causes a deWcient detoxiWcation
through the loss of protein expression [23, 28]. Other
genes, such as GSTP1, are also known to detoxify reactive
epoxides of PAHs [10]. We did not include these genes in
our study. Possibly, additional studies including GSTP1
could elucidate gene–environment interactions in RCC. In
addition, we are aware that other CYP1A1 variants such as
CYP1A1*4, have previously been described in RCC [3], but
since this variant has a population frequency of only 3%
[11], we did not include this variant in our analyses.
In a case-only design, the assumption of independence
of genotype and exposure is required for a valid interpreta-
tion of the interaction odds ratio. Although it could be
hypothesized that polymorphisms in metabolic genes could
inXuence smoking behaviour, a large study on healthy con-
trols from the database of the International Collaborative
Study on Genetic Susceptibility to Environmental Carcino-
gens showed no association between CYP1A1 and GST1
genotype and smoking [29].
The important strengths of our study include the design
of the study, a case-only design, which needs smaller sam-
ple sizes as compared to a case–control design. However,
even using a case-only design, the population was too small
to conduct subgroup analyses such as the comparison of ex-
smokers and current smokers. Selection and recall bias are
unlikely in our study since exposure was assessed prior to
cancer diagnosis and only incident cancer cases were
included. Moreover, it is unlikely that selection bias has
occurred in the collection of tissue material. Since we used
a case-only design to assess the magnitude of the associa-
tion between smoking and CYP1A1 and GST1 genotype in
RCC, we were only able to detect departure from multipli-
cative interaction [30, 31]. In the epidemiologic literature,
there continues to be discussion on the appropriate deWni-
tion and interpretation of interaction, suggesting that espe-
cially departure from an additive model represents the true
underlying model of joint eVects [32, 33]. As a case-only
design is only able to detect departure from multiplicative
interaction, we could have missed a departure from additive
interaction. Moreover, it was not possible to estimate the
main eVects of smoking and CYP1A1 and GST1 genotype
on RCC risk due to the case-only design.
To our knowledge, this is the Wrst study to consider a
possible interaction between CYP1A1*2A, CYP1A1*2C
and GST1 genotype and smoking in patients with renal
cancer. Our results suggest a possible modest interaction
between CYP1A1*2C genotype and current smoking and
between GST1 null genotype and current smoking. Also,
results indicate a possible interaction between cases with
both a variant in CYP1A1 and GST1 null genotype and
current smoking. These results suggest that the risk of RCC
in smokers may even be more increased in the presence of
the CYP1A1*2C heterozygous or homozygous genotype or123
World J Urol (2008) 26:103–110 109the GST1 null genotype. However, none of the observed
associations reached statistical signiWcance although we
observed a moderate trend towards statistical signiWcance.
Results should be replicated in future, larger studies before
a deWnite conclusion on gene–environment interactions
between CYP1A1 and GST1 genotype and smoking in
RCC can be drawn.
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